Acorda Therapeutics, Inc. (ACOR)
Seite 2 von 4 Neuester Beitrag: 03.04.24 17:14 | ||||
Eröffnet am: | 07.02.17 05:27 | von: Chalifmann3 | Anzahl Beiträge: | 88 |
Neuester Beitrag: | 03.04.24 17:14 | von: Balu4u | Leser gesamt: | 32.485 |
Forum: | Hot-Stocks | Leser heute: | 5 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 > |
Zahlen für Q3/19
- Umsätze 48 Mio. $
- AMPYRA® (dalfampridine) 38 Mio. $
- INBRIJA 5 Mio. $
- AMPYRA® (dalfampridine) 38 Mio. $
- Verlust 264 Mio. $
- 278 Mio. $ Goodwill Impairment
- 278 Mio. $ Goodwill Impairment
- Cash 253 Mio. $
- MK 72 Mio. $
http://ir.acorda.com/investors/investor-news/...-30-2019/default.aspx
Hedge Fund "Point72" steigt mit 9,8% ein
https://seekingalpha.com/news/...rda-up-16-premarket-on-point72-stake
Zeitpunkt: 17.02.20 10:00
Aktion: Löschung des Beitrages
Kommentar: Verdacht auf Spam-Nutzer
Zahlen für Q4/19 und FY2019
- Umsatz 50,5 Mio. $
- AMPYRA ~41 Mio. $ (VJQ ~64 Mio. $)
- INBRIJA ~6 Mio. $
- Royalty 3 Mio. $
- AMPYRA ~41 Mio. $ (VJQ ~64 Mio. $)
- Umsatz 192 Mio. $ (VJ 471 Mio. $)
- AMPYRA ~163 Mio. $ (VJ 455 Mio. $)
- INBRIJA ~15 Mio. $
- Royalty ~12 Mio. $
- AMPYRA ~163 Mio. $ (VJ 455 Mio. $)
Sehr erschreckend wie stark die Umsätze von AMPYRA innerhalb nur eines Jahres um fast 300 Mio. $ zurück gegangen sind und auch in 2020 weiter zurück gehen werden.
Ausblick 2020
- Umsätze 120-150 Mio. $
- AMPYRA® (dalfampridine) 85-110 Mio. $
- INBRIJA® 35-40 Mio. $
- INBRIJA peak sales revised to $300 - $500 million
- AMPYRA® (dalfampridine) 85-110 Mio. $
- Cash 169 Mio. $
- MK 86 Mio. $
http://ir.acorda.com/investors/investor-news/...-Results/default.aspx
https://www.fiercepharma.com/pharma/...-inbrija-after-lackluster-year
Dalfampridine ER Tablets, Generic Version of Ampyra, Now Available in US, Mylan Announces
https://multiplesclerosisnewstoday.com/2018/09/25/...available-in-us/
https://www.analystratings.com/articles/...-acorda-therapeutics-acor/
For the quarter ended March 31, 2020, the Company reported INBRIJA net revenue of $4.4 million, compared to $1.3 million for the same quarter in 2019.
For the quarter ended March 31, 2020, the Company reported AMPYRA net revenue of $20.1 million compared to $40.1 million for the same quarter in 2019. In September 2018, AMPYRA lost its exclusivity and generics entered the market. Consequently, the Company expects AMPYRA revenue to continue to decline.
http://ir.acorda.com/investors/investor-news/...s-Update/default.aspx
..und die aktuelle Pipeline wird aktuell wohl auch nicht weiterentwickelt wenn ich das richtig verstanden habe?!
As a result of declines in physician office visits due to COVID-19 stay-at-home orders, the Company is withdrawing its previously announced 2020 INBRIJA net revenue guidance. This also necessitates the withdrawal of 2020 total net product revenue. Acorda continues to expect INBRIJA peak sales to be $300 - $500 million.
Zahlen für Q1/20
- AMPYRA Umsatzprognose für 2020 bekräftigt
- INBRIJA Umsatzprognose für 2020 zurückgezogen (35-40 Mio. $)
- Q1/20 Umsatz 24,5 Mio. $
- AMPYRA® (dalfampridine) 20,1 Mio. $
- INBRIJA® (levodopa inhalation powder) 4,4 Mio. $
- AMPYRA® (dalfampridine) 20,1 Mio. $
- Verlust 6 Mio. $ (Non-GAAP 24)
- Cash 126 Mio. $
- MK 36 Mio. $
"For the full-year 2020, Acorda continues to expect AMPYRA net revenue to be $85 - $110 million, and operating expenses to be $170 - $180 million. The operating expense guidance is a non-GAAP projection that excludes restructuring costs and share-based compensation as more fully described below under “Non-GAAP Financial Measures.”
As a result of declines in physician office visits due to COVID-19 stay-at-home orders, the Company is withdrawing its previously announced 2020 INBRIJA net revenue guidance. This also necessitates the withdrawal of 2020 total net product revenue. Acorda continues to expect INBRIJA peak sales to be $300 - $500 million."
http://ir.acorda.com/investors/investor-news/...s-Update/default.aspx
AMPYRA ist auf dem absteigenden Ast
Das Management hätte dieses Asset verkaufen sollen, noch bevor Generika auf den Markt kamen.
- 2018-er Umsatz ~455 Mio. $
- 2019-er Umsatz ~163 Mio. $
- 2020-er Prognose ~85-110 Mio. $
Es wäre interessant zu wissen wieviel % der Kosten auf AMPYRA entfallen.
Zahen für Q2/20
- Q2/20 Umsatz 33,6 Mio. $
- AMPYRA® (dalfampridine) 26,1 Mio. $
- INBRIJA® (levodopa inhalation powder) 4,7 Mio. $
- AMPYRA® (dalfampridine) 26,1 Mio. $
- Verlust 17 Mio. $
- Cash 104 Mio. $
- MK 31 Mio. $
"For the full-year 2020, Acorda continues to expect AMPYRA net revenue to be $85 - $110 million, and operating expenses to be $170 - $180 million."
http://ir.acorda.com/investors/investor-news/...-Results/default.aspx